Haj-Yehia, Elias http://orcid.org/0000-0002-6602-7025
Mincu, Raluca I.
Korste, Sebastian
Lampe, Lena
Margraf, Simone M.
Michel, Lars
Mahabadi, Amir A.
Ferdinandy, Péter
Rassaf, Tienush
Totzeck, Matthias
Funding for this research was provided by:
Deutsche Gesellschaft für Kardiologie-Herz und Kreislaufforschung. (D02/2022)
Deutsche Forschungsgemeinschaft (RA969/12-1)
Nemzeti Kutatási Fejlesztési és Innovációs Hivatal (RRF-2.3.1-21-2022-00003)
Universitätsklinikum Essen
Article History
Received: 6 September 2023
Accepted: 17 October 2023
First Online: 13 November 2023
Declarations
:
: M.T. and T.R. report personal fees and others from Edwards and Novartis, Bristol Myers Squibb, Bayer, Daiichi Sankyo and Astra Zeneca, which are outside the submitted work. T.R. cofounded Bimyo, a company focusing on the development of cardioprotective peptides. All other authors declare no conflict of interest. P.F. is the founder and CEO of Pharmahungary Group, a group of R&D companies holding patents on cardioprotective oligonucleotides and providing R&D services for drug development.
: All procedures were in accordance with the ethical standards of the institutional ethics committees of the participating centers and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.